Eckert & Ziegler reported modest year-over-year growth in its top and bottom lines for the first quarter, while adjusted operating profit slipped. The Germany-based isotope specialist recorded sales of 72.90 million euros and net income of 10.40 million euros for the quarter, representing a 7% increase versus the same quarter last year. Diluted earnings per share amounted to 0.17 euros.
Although headline revenue and net income rose, adjusted earnings before interest and taxes declined by 2% in the quarter. Company commentary linked the fall in adjusted EBIT to a weaker product mix within the Isotope Products segment. That segment also experienced lower sales earlier in the quarter, which the company identified as a material factor behind the margin contraction.
Revenue growth was driven by the Medical segment, where the company reported higher sales across several product and service lines. Specifically, medical revenue benefited from increased sales of pharmaceutical radioisotopes and generators, as well as from expanded contract development and manufacturing organization - CDMO - services.
Management left its full-year 2026 targets unchanged, reaffirming guidance that projects annual sales of around 320 million euros and adjusted EBIT of approximately 80 million euros. The reaffirmation indicates no upward or downward revision to the company’s published outlook based on first-quarter results.
The quarter therefore presents a mixed operational picture: growth in overall sales and net income accompanied by pressure on adjusted operating profitability tied to product-mix dynamics in a single segment. For stakeholders focused on the healthcare and specialty manufacturing segments, the Q1 figures underscore the role of the Medical business in driving near-term revenue growth, while highlighting margin sensitivity in isotope product lines.
Financial snapshot
- Sales: 72.90 million euros in Q1 (up 7% year-over-year)
- Net income: 10.40 million euros in Q1 (up 7% year-over-year)
- Earnings per share: 0.17 euros
- Adjusted EBIT: down 2% in Q1
- Full-year 2026 guidance: sales ~320 million euros; adjusted EBIT ~80 million euros (reaffirmed)
Sector relevance
- Healthcare and biotech - medical radioisotopes and CDMO services influence revenue trends.
- Specialty manufacturing - isotope product-mix shifts affect operating margins.